Arrowhead Pharmaceuticals Reports Strong Q1 Profitability Driven by Collaborations and Major Pipeline Progress

summarizeSummary

Arrowhead Pharmaceuticals reported a significant return to profitability in Q1 FY2026, driven by strong collaboration revenues and key pipeline advancements, alongside a substantial $930 million capital raise.

check_boxKey Events

• Return to Profitability

  Reported net income of $30.8 million for Q1 FY2026, a significant turnaround from a net loss of $173.1 million in the same period last year, driven by a substantial increase in revenue to $264.0 million from $2.5 million.

• Major Collaboration Revenue

  Recognized $229.5 million in revenue from the Sarepta collaboration and $34.2 million from the Novartis collaboration, including a $200 million upfront payment from Novartis and a $200 million milestone payment from Sarepta.

• Key Regulatory Approvals and Designations

  Received FDA approval for REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome (FCS) and Breakthrough Therapy designation for plozasiran in severe hypertriglyceridemia (SHTG). China NMPA also approved REDEMPLO, triggering a $10 million milestone.

• Substantial Capital Raise

  Completed upsized offerings of convertible senior notes and common stock/pre-funded warrants in January 2026, raising gross proceeds of $930.0 million, significantly strengthening the company's liquidity.

auto_awesomeAnalysis

Arrowhead Pharmaceuticals' latest 10-Q filing details a significant return to profitability in its fiscal first quarter, with net income of $30.8 million compared to a $173.1 million loss in the prior year. This turnaround was primarily fueled by substantial revenue recognition from collaboration agreements, including $229.5 million from Sarepta and $34.2 million from Novartis. The report also consolidates several key positive developments previously announced, such as the FDA approval of REDEMPLO for Familial Chylomicronemia Syndrome (FCS) and Breakthrough Therapy designation for plozasiran in severe hypertriglyceridemia (SHTG). Furthermore, the company initiated new clinical trials and reported positive interim data for its obesity programs. A significant subsequent event was the completion of upsized offerings of convertible senior notes and equity, raising gross proceeds of $930.0 million, which substantially strengthens the balance sheet. The dismissal of a patent infringement suit by Ionis Pharmaceuticals also removes a potential legal overhang. This comprehensive report confirms a period of strong operational and financial execution, positioning the company for continued growth.